

SEQUENCE LISTING

<110> Siemens AG

<120> A method for predicting a clinical response of a patient
suffering from or at risk of developing cancer towards a given
mode of treatment

<130> 200720895 HEN / SEI

<160> 15

<170> PatentIn version 3.3

<210> 1

<211> 24

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 1

cggaaccag ctaccgcgta acac

24

<210> 2

<211> 20

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 2

gcgacccga cttctacaag

20

<210> 3

<211> 19

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 3

ggagggagga gcagctgaa

19

<210> 4

<211> 23

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 4

cctacctgcc gcacctggg act

23

<210> 5

<211> 24

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 5

accatgtctg gaagtgacta tgcc

24

<210> 6

<211> 26

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 6

aatctgctgt cttcatctgt gaatgt

26

<210> 7

<211> 35

<212> DNA

<213> Artificial

<220>

<223> SPON-1

<400> 7
agagtcatgt tacccattct tagccattaa cctgg 35

<210> 8
<211> 29
<212> DNA
<213> Artificial

<220>
<223> SPON-1

<400> 8
cattttaaaa tcctgatttt ggagactta 29

<210> 9
<211> 24
<212> DNA
<213> Artificial

<220>
<223> SPON-1

<400> 9
gcttcttata aattcccat tgca 24

<210> 10
<211> 28
<212> DNA
<213> Artificial

<220>
<223> SPON-2

<400> 10
tgtagacagc gcctcagttc cagaaacg 28

<210> 11
<211> 19
<212> DNA
<213> Artificial

<220>
<223> SPON-2

<400> 11
ccczagcaggg acaatgaga 19

<210> 12
<211> 18
<212> DNA
<213> Artificial

<220>
<223> SPON-2

<400> 12
agacctcgca gtccagcg 18

<210> 13
<211> 19
<212> DNA
<213> Artificial

<220>
<223> SPON-2

<400> 13
ccctctggtg gccggcacg 19

<210> 14
<211> 20
<212> DNA
<213> Artificial

<220>
<223> SPON-2

<400> 14
ccgaccatct ctgcactgaa 20

<210> 15
<211> 21
<212> DNA
<213> Artificial

<220>

<223> SPON-2

<400> 15
agaagcaagg ttgggaaagg a

21